SBA Member, 14.09.2017
BC|RQUEST provides researchers direct access to genomic and phenotypic data from the United States and Europe
(13 Sept, 2017) Basel, Switzerland and Helsinki, Finland - BC Platforms, a world leader in genomic data management and analysis solutions, today announces it has launched BC|RQUEST, a unique resource that enables integrated analytics of genomic and clinical data. BC|RQUEST facilitates browsing and analytics of genomic and clinical data that has been aggregated across biobanks and streamlines collaboration between biobanks and the pharmaceutical industry. Patient privacy is protected since individual level
patient data is not exposed.
BC|RQUEST will be used by members of the Open Biobank Research Enhancement Alliance (OBREA), formed by BC Platforms to connect biobanks, technology
enablers, researchers and industry. Biobanks joining at this initial phase are geographically diverse, from Estonia, Mexico, Finland, Poland, the United States and the UK, representing more than 2 million people. By participating in a global research network, biobanks can increase the visibility and utility of their samples and data, supporting their sustainability. Researchers, in turn, can leverage the collective assets and diversity of global biobanks to discover potential breakthroughs.
BC Platforms’ vision is to build the world’s leading analytics resource for healthcare and industry by 2020, providing access to diverse genomic and clinical data from biobanks, comprising more than 5 million people. Microsoft will provide the cloud infrastructure for indexing and accessing the information globally and securely through the Microsoft Azure cloud platform.
Tero Silvola, CEO of BC Platforms, commented; “Genomic data is notoriously difficult to collect, harmonise and integrate with phenotypic data on a global scale. Through this initiative we make it possible for researchers to immediately access the combined data assets of a global network of biobanks, saving them the time and expense involved in locating suitable samples and harmonizing multiple sources of data. In addition, through participation in the network, biobanks can support their operations and enhancements as well as experience a best practice approach to data management and sharing.”
Dr Tõnu Esko, PhD, Deputy Director of Research, Estonian Biobank, Estonian Genome Center, at the University of Tartu, commented on the collaboration; “We are delighted to be part of this exciting network. Estonia was amongst the first to use biomarkers combined with medical history and lifestyle information in the study of common diseases and traits at a truly national scale. Our data is obtained from many different databases including registries, the national biobank, and local hospital electronic health
records. This collaboration with BC Platforms will help us merge and organize our data in a format that will make it useful for others, such as industry, for the development of new drugs.”
Geralyn Miller, Director, Microsoft Genomics, said; “As part of OBREA, we are pleased to provide Microsoft’s global reach and cloud computing infrastructure for analysis of massive amounts of real-world data in order to generate insights into the mechanisms of disease and possible treatments. We strongly believe that the combination of genomics and technology will transform the whole of healthcare and life science working practices. This is a major step towards supporting precision medicine.”
- ENDS –
For more information, please contact:
Tero Silvola, CEO
tel. +358 40 590 5733
Katja Stout, Pure Communications
Tel: +44 7789435990
Notes to editors:
About BC Platforms
BC Platforms is a world leader in providing powerful genomic data management and analysis solutions. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms' vision is to revolutionize decision making in drug development to bring clinical benefits to patients. Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by 20 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development located in Helsinki, Finland, and sales and marketing based in London, Boston, and Vancouver. For more information, please visit www.bcplatforms.com or follow us on Twitter @BCPlatforms.
About the Estonian Genome Center
The Estonian Genome Center of the University of Tartu (EGCUT, www.biobank.ee) is a research institute of the University of Tartu whose aim is to promote the development of human genetic research, collecting information on health issues and genetics of the Estonian population, and implement genomics data in medical practice, with the aim to improve population health. The Estonian Biobank (including 50,000 participants), hosted by EGCUT, is one of the world’s leading resources for developing precision medicine applications with its forward-looking laws, longitudinal digital health repositories and availability of biological samples. The EGCUT is one of the first biobanks to deliver genetic feedback to all of its active participants and develop pipelines to implement genomic research to improve public health.
For more information on Microsoft Genomics, please visit